Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
UPDATE: Galmed Pharma (GLMD) Reports Q2 Loss of $0.17
August 2, 2018 7:47 AM EDT(Updated - August 2, 2018 7:48 AM EDT)
Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS Loss of $0.17, versus ($0.16) reported last year. Revenue for the quarter came in at $270 thousand versus the consensus estimate of $270 thousand.
Financial Summary - First Quarter 2018 vs. First Quarter 2017:
Cash and cash equivalents and marketable securities totaled $94.1 million as of June 30, 2018, compared to $19.0 million at December 31, 2017. The increase is mainly... More